These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3201525)

  • 21. Risk factors for toxicity in elderly patients given aminoglycosides once daily.
    Paterson DL; Robson JM; Wagener MM
    J Gen Intern Med; 1998 Nov; 13(11):735-9. PubMed ID: 9824518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.
    Tablan OC; Reyes MP; Rintelmann WF; Lerner AM
    J Infect Dis; 1984 Feb; 149(2):257-63. PubMed ID: 6421944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative cost effectiveness of gentamicin and tobramycin.
    Holloway JJ; Smith CR; Moore RD; Feroli ER; Lietman PS
    Ann Intern Med; 1984 Dec; 101(6):764-9. PubMed ID: 6437310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.
    Plaut ME; Schentag JJ; Jusko WJ
    J Med; 1979; 10(4):257-66. PubMed ID: 294466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aminoglycoside-induced nephrotoxicity.
    Wargo KA; Edwards JD
    J Pharm Pract; 2014 Dec; 27(6):573-7. PubMed ID: 25199523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides.
    Yee GC; Evans WE
    Pharmacotherapy; 1981; 1(1):55-75. PubMed ID: 6927603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.
    Streetman DS; Nafziger AN; Destache CJ; Bertino AS
    Pharmacotherapy; 2001 Apr; 21(4):443-51. PubMed ID: 11310518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prediction of aminoglycoside nephrotoxicity (author's transl)].
    Whelton A
    Nouv Presse Med; 1978 Nov; 7(42):3838-43. PubMed ID: 714689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.
    Matthews I; Kirkpatrick C; Holford N
    Br J Clin Pharmacol; 2004 Jul; 58(1):8-19. PubMed ID: 15206987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for nephrotoxicity in patients treated with aminoglycosides.
    Moore RD; Smith CR; Lipsky JJ; Mellits ED; Lietman PS
    Ann Intern Med; 1984 Mar; 100(3):352-7. PubMed ID: 6364908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia.
    Etzel JV; Nafziger AN; Bertino JS
    Antimicrob Agents Chemother; 1992 Mar; 36(3):679-81. PubMed ID: 1622185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report.
    Fee WE; Vierra V; Lathrop GR
    J Antimicrob Chemother; 1978 May; 4 Suppl A():31-6. PubMed ID: 659347
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.
    Mann HJ; Wittbrodt ET; Baghaie AA; Cerra FB
    Pharmacotherapy; 1998; 18(2):371-8. PubMed ID: 9545157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods.
    Franson TR; Quebbeman EJ; Whipple J; Thomson R; Bubrick J; Rosenberger SL; Ausman RK
    Crit Care Med; 1988 Sep; 16(9):840-3. PubMed ID: 3402229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobramycin and gentamicin are equally safe for neonates: results of a double-blind randomized trial with quantitative assessment of renal function.
    Itsarayoungyuen S; Riff L; Schauf V; Hamilton L; Otrembiak J; Vidyasagar D
    Pediatr Pharmacol (New York); 1982; 2(2):143-55. PubMed ID: 12760406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients.
    Schentag JJ
    J Clin Pharmacol; 1983 Oct; 23(10):473-83. PubMed ID: 6643700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.